Lexicon Pharmaceuticals Inc. (LXRX) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.44 (+1.41% 1D, market cap $631.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $645.3M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 32.6 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While LXRX currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.51) forces dealer call-delta covering toward $2.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Lexicon Pharmaceuticals Inc. (LXRX) advanced +1.41% to $1.44, trading at 22% of its 52-week range ($1.1 – $2.68). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
scanx.trade report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial o
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing pivotal Phase 3
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of sotagliflozin on platelet
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +729.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LXRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LXRX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Lexicon Pharmaceuticals Inc. (LXRX) ranks #904 by composite RQD confidence (26/100, grade E) and #408 by equity capitalization ($631.8M). Within this direct 5-issuer industry benchmark cohort, LXRX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with LXRX at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LXRX
ACTIVE
Lexicon Pharmaceuticals Inc. | E | 26/100 | — | 96.0% | -31.5% | +1.41% | $631.8M | Benchmark Subject |
| IMMX Immix Biopharma Inc. | E | 29/100 | — | — | -35.0% | -5.47% | $636.7M | /immx-vs-lxrx → |
| ABUS Arbutus Biopharma Corporation | E | 18/100 | — | — | -35.0% | -4.99% | $645.3M | /abus-vs-lxrx → |
| ANL Adlai Nortye Group Ltd. | D | 46/100 | — | — | — | -1.88% | $615.0M | /anl-vs-lxrx → |
| OLMA Olema Pharmaceuticals Inc. | E | 29/100 | — | — | -32.8% | +1.00% | $612.5M | /olma-vs-lxrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported GAAP revenue of $49.8M (+729.9% vs. FY2024 revenue of $6.0M , and +4386.8% cumulative change since FY2023) , GAAP net income of -$50.3M, operating cash flow of -$67.9M, and free cash flow of -$67.9M (+62.3% YoY). On the balance sheet, LXRX closed FY2025 with $185.0M in total assets against $49.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $49.8M | -$50.3M | -$67.9M | -$67.9M | $185.0M | $49.4M |
| FY2024 (FY) | 2024-12-31 | $6.0M | -$200.4M | -$178.8M | -$179.8M | $298.4M | $100.3M |
| FY2023 (FY) | 2023-12-31 | $1.1M | -$177.1M | -$161.9M | -$161.9M | — | — |
As of 2026-11-03, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.44 (+1.41% 1D, market cap $631.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $645.3M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
LXRX last traded at $1.44 (+1.41% on volume of 2,020,779 shares), positioning the stock -22.16% below its 50-day simple moving average ($1.85) and -23.81% below its 200-day simple moving average ($1.89). Across its 52-week range of $1.10 to $2.68, LXRX sits at the 21.5% percentile with a 14-day RSI of 32.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.28 to $1.60).
Lexicon Pharmaceuticals Inc. (LXRX) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.44 (+1.41% 1D, market capitalization $631.8M).
Lexicon Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.7B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported $49.8M in annual revenue (up from $6.0M in FY2024, +729.9% YoY) and -$50.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.1M revenue, -$177.1M net income) through FY2025, LXRX scaled operating cash flow to -$67.9M and free cash flow to -$67.9M, backed by $185.0M in total assets against $49.4M in total debt.
The main 2nd-order channel visible in the data is liquidity sensitivity: the macro signal implies that LXRX's price responds to shifts in net liquidity, so a tightening of liquidity conditions, as reflected in the Fed, TGA, and RRP components, would be a ripple risk. Investors should also watch the high-yield spread, which the signal cites at +2 bps, as an indicator of financing conditions for cash-consuming issuers.
Real-time company headlines, analyst actions, and sector developments for Lexicon Pharmaceuticals Inc. (LXRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
scanx.trade report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial o
Long LXRX at $1.42 targeting $1.79. The Butterfly liquidity signal scores 92/100 as a Macro Tailwind with a 2.97x Net Liquidity beta, and revenue grew from $1.1M in FY 2023 to $49.8M in FY 2025.. Institutional whale score is 3/20 and the risk/reward vs. the $1.10 52-week low is skewed heavily in favor of bulls.
@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (96.0%) holds, EPS grows into the multiple faster than bears think.
I respect the product at Lexicon Pharmaceuticals Inc., but the stock at $1.42 is a different story. ROIC is -31.5%, FCF yield is -10.3%, and the Fundamental Cash Engine pillar scores only 4 of 20 on the RQD rating.. FCF yield is -10.3% and RQD sits at 26/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: